A Therapeutic Silencing RNA Targeting Hepatocyte TAZ Prevents and Reverses Fibrosis in Nonalcoholic Steatohepatitis in Mice

Xiaobo Wang, Mark R. Sommerfeld, Kerstin Jahn‐Hofmann, Bishuang Cai, Aveline Filliol, Helen E. Remotti, Robert F. Schwabe, Aimo Kannt, Ira Tabas – 23 July 2019 – Nonalcoholic steatohepatitis (NASH) is emerging as a major public health issue and is associated with significant liver‐related morbidity and mortality. At present, there are no approved drug therapies for NASH.

Zinc Maintenance Therapy for Wilson Disease: A Comparison Between Zinc Acetate and Alternative Zinc Preparations

Michelle A. Camarata, Aftab Ala, Michael L. Schilsky – 23 July 2019 – We evaluate Wilson disease (WD) treatment with zinc acetate (U.S. Food and Drug Administration approved) and alternative zinc salts. Studies examining zinc therapy in WD are few, and data on alternative zinc salts are limited. We describe one of the largest recent studies of zinc therapy in WD.

Subscribe to